hVIVO Revenue and Competitors
Estimated Revenue & Valuation
- hVIVO's estimated annual revenue is currently $50.5M per year.
- hVIVO's estimated revenue per employee is $155,000
Employee Data
- hVIVO has 326 Employees.
- hVIVO grew their employee count by 7% last year.
hVIVO's People
Name | Title | Email/Phone |
---|---|---|
1 | Chief Scientific Officer | Reveal Email/Phone |
2 | Recruitment Officer | Reveal Email/Phone |
3 | Head Quality Assurance | Reveal Email/Phone |
4 | VP, Clinical Operations | Reveal Email/Phone |
5 | Enrolment Officer | Reveal Email/Phone |
6 | Enrolment Officer | Reveal Email/Phone |
7 | Associate Director Project Management | Reveal Email/Phone |
8 | Medical Director | Reveal Email/Phone |
9 | Associate Director, Laboratory Project Operations | Reveal Email/Phone |
10 | Senior Director, Clinical Sciences | Reveal Email/Phone |
hVIVO Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.5M | 29 | -12% | N/A | N/A |
#2 | $15.7M | 101 | 5% | N/A | N/A |
#3 | $87.9M | 405 | 25% | $292M | N/A |
#4 | $2.6M | 470 | 16% | $631.7M | N/A |
#5 | $14.9M | 96 | -8% | $81M | N/A |
#6 | $44.8M | 231 | 0% | $132.9M | N/A |
#7 | $7.6M | 49 | -37% | N/A | N/A |
#8 | $17.4M | 112 | 12% | N/A | N/A |
#9 | $334.6M | 1349 | 11% | £994.6M | N/A |
#10 | $830.2M | 5356 | 8% | N/A | N/A |
What Is hVIVO?
hVIVO, part of Open Orphan plc, was established in 1989 as a spin out from Queen Mary University, London, and is a clinical development services business pioneering human disease models based upon viral challenge. Using human challenge studies to establish early proof-of-concept, hVIVO's clinical trial platform can accelerate drug and vaccine development in respiratory and infectious diseases, hVIVO has leveraged its insights in established human disease challenge models in influenza (â??Fluâ??), respiratory syncytial virus (â??RSVâ??) and human rhinovirus (â??HRVâ??) to expand the use of viral challenge in additional respiratory indications including asthma, chronic obstructive pulmonary disease (â??COPDâ??) and cough and in special populations.\nhVIVO was acquired by Open Orphan PLC in January 2020 and in now listed on the London AIM as ORPH.
keywords:N/AN/A
Total Funding
326
Number of Employees
$50.5M
Revenue (est)
7%
Employee Growth %
N/A
Valuation
N/A
Accelerator
hVIVO News
The study was conducted by its subsidiary hVIVO in conjunction with the Imperial College London, the Vaccine Taskforce and Department of...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $15M | 326 | 9% | N/A |
#2 | $35M | 326 | 6% | N/A |
#3 | $59.1M | 326 | 5% | N/A |
#4 | $15M | 326 | 6% | N/A |
#5 | $59.1M | 326 | N/A | N/A |